Antithrombotic therapy in peripheral artery disease
Antithrombotic therapy in peripheral artery disease Peripheral artery disease (PAD) is a common circulatory problem characterized by narrowing or blockages in the peripheral arteries, primarily affecting the limbs. This condition can lead to symptoms like claudication, ischemic rest pain, and in severe cases, critical limb ischemia, which may result in limb loss. Managing PAD involves a multifaceted approach that includes lifestyle modifications, revascularization procedures, and crucially, antithrombotic therapy to reduce the risk of cardiovascular events and limb-related complications.
Antithrombotic therapy in peripheral artery disease Antithrombotic therapy in PAD primarily aims to prevent thrombotic events, such as myocardial infarction, stroke, and limb ischemia, by inhibiting platelet aggregation and thrombin formation. The two main classes of antithrombotic agents used in PAD are antiplatelet drugs and anticoagulants. Antiplatelet agents are considered the cornerstone of PAD management due to their proven benefits in reducing cardiovascular events.
Aspirin is the most commonly prescribed antiplatelet agent for PAD patients. It irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production, which reduces platelet aggregation. Multiple clinical trials have demonstrated that aspirin reduces the risk of major cardiovascular events in PAD patients. The typical dose ranges from 75 to 325 mg daily, with lower doses preferred to minimize gastrointestinal side effects. Antithrombotic therapy in peripheral artery disease
Clopidogrel, a P2Y12 receptor inhibitor, has also shown efficacy in PAD, especially in patients who are aspirin-intolerant or where dual antiplatelet therapy (DAPT) is considered. While DAPT with aspirin and clopidogrel has been explored mainly in the context of secondary prevention post-revascularization, some evidence suggests a potential benefit in reducing limb events, although the optimal duration and patient selection require further clarification.
In recent years, the combination of aspirin and low-dose rivaroxaban (a direct oral anticoagulant) has gained attention. The VOYAGER PAD trial demonstrated that this combination significantly reduced ischemic events in patients with PAD undergoing revascularization, with a manageable increase in bleeding risk. This has led to evolving guidelines endorsing more personalized approaches based on individual risk profiles. Antithrombotic therapy in peripheral artery disease
The role of anticoagulants such as warfarin is limited in PAD management due to their higher bleeding risk and lack of additional benefit over antiplatelet therapy alone. However, in specific cases like concomitant atrial fibrillation, anticoagulation becomes essential.
Antithrombotic therapy in peripheral artery disease Beyond pharmacotherapy, comprehensive management includes addressing risk factors such as smoking cessation, lipid control, diabetes management, and exercise therapy. Revascularization procedures may be indicated in cases with critical limb ischemia or significant stenoses, but antithrombotic therapy remains central both pre- and post-procedure to prevent thrombosis and restenosis.
Antithrombotic therapy in peripheral artery disease In summary, antithrombotic therapy is a vital component of PAD management, with aspirin being the foundation. The addition of other agents like clopidogrel or low-dose rivaroxaban can offer additional benefits for selected patients. Tailoring therapy to individual risk profiles, along with lifestyle and risk factor management, provides the best strategy to improve outcomes and quality of life for patients with PAD.
